Waters Corporation vs Bristol Myers Squibb

Side-by-side comparison of AI visibility scores, market position, and capabilities

AI visibility is closely matched (76 vs 80)
Waters Corporation logo

Waters Corporation

LeaderHealthcare Tech

Analytical Instruments

Waters Corporation (WAT) reported ~$2.97B revenue in FY2024. Premier maker of liquid chromatography instruments and mass spectrometers used in pharmaceutical quality control and research. HQ: Milford, MA.

AI VisibilityBeta
Overall Score
B76
Category Rank
#70 of 596
AI Consensus
85%
Trend
stable
Per Platform
ChatGPT
79
Perplexity
73
Gemini
74

About

Waters Corporation is the global leader in analytical instruments and detection technologies for the life science, pharmaceutical, and materials science industries, best known for its high-performance liquid chromatography (HPLC) systems, ultra-high performance liquid chromatography (UPLC) platforms, and mass spectrometry instruments used in drug discovery, quality control, and regulatory compliance. Founded in 1958 by Jim Waters, the company pioneered the commercialization of HPLC technology that is now the standard method for separating and analyzing chemical mixtures in pharmaceutical manufacturing.

Full profile
Bristol Myers Squibb logo

Bristol Myers Squibb

LeaderHealthcare Tech

Enterprise

Princeton NJ biopharma (NYSE: BMY) at $48.3B 2024 revenue; Eliquis $13.3B, Opdivo $9.2B, Cobenfy schizophrenia launch; $23B acquisitions (Karuna+Mirati+RayzeBio) building next pipeline vs. Pfizer and Merck.

AI VisibilityBeta
Overall Score
A80
Category Rank
#18 of 596
AI Consensus
83%
Trend
stable
Per Platform
ChatGPT
78
Perplexity
78
Gemini
80

About

Bristol Myers Squibb (BMS) is a Princeton, New Jersey-based global biopharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: BMY) as an S&P 500 Healthcare component — discovering, developing, and delivering innovative medicines for serious diseases including cancer, cardiovascular disease, immunology, and neuroscience through approximately 34,000 employees worldwide. In fiscal year 2024, BMS reported total revenue of $48.3 billion (+7% year-over-year), with its Growth Portfolio generating $22.6 billion (+17%), driven by blockbusters Eliquis ($13.3B anticoagulant), Opdivo ($9.2B immuno-oncology), and Revlimid ($5.8B multiple myeloma). New product revenue surged 77% to $3.6 billion, led by schizophrenia treatment Cobenfy (formerly KarXT), CAR-T therapy Breyanzi, anemia drug Reblozyl, and Opdualag checkpoint inhibitor combination. CEO Dr. Christopher Boerner assumed leadership in November 2023, accelerating BMS's pipeline expansion through three transformative acquisitions in 2024: Karuna Therapeutics ($14B, Cobenfy/KarXT for schizophrenia and Alzheimer's agitation), Mirati Therapeutics ($4.8B, KRAS-targeted oncology), and RayzeBio ($4.1B, radiopharmaceutical cancer therapy).

Full profile

AI Visibility Head-to-Head

76
Overall Score
80
#70
Category Rank
#18
85
AI Consensus
83
stable
Trend
stable
79
ChatGPT
78
73
Perplexity
78
74
Gemini
80
73
Claude
84
75
Grok
77

Key Details

Category
Analytical Instruments
Enterprise
Tier
Leader
Leader
Entity Type
company
company

Capabilities & Ecosystem

Capabilities

Only Waters Corporation
Analytical Instruments

Integrations

Only Waters Corporation
Only Bristol Myers Squibb
Waters Corporation is classified as company. Bristol Myers Squibb is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.